Personalised Treatment for Cancer with AI

-

Hi Folks!! Follow our blog on Instagram
Artificial intelligence is accelerating personalized medicine, cancer research, and cancer care. It has numerous applications throughout the field of oncology, from cancer detection and diagnosis to the characterization of tumors and their environment, drug discovery, and prediction of treatment response and outcomes.

"The implementation of artificial intelligence in cellular therapy is new and may be a game-changer, offering new clinical options to patients," said Ludwig Lausanne's Alexandre Harari, who led the study with graduate student Rémy Pétremand.


Cellular immunotherapy involves extracting immune cells from a patient's tumor, optionally engineering them to enhance their natural abilities to combat cancer and reintroducing them to the body after they've been expanded in culture. T cells are one of the two main types of white blood cells, or lymphocytes, that circulate in the blood and patrol for virally infected or cancerous cells.

Using artificial intelligence, Ludwig Cancer Research scientists have developed a powerful predictive model for identifying the most potent cancer killing immune cells for use in cancer immunotherapies.
Combined with additional algorithms, the predictive model, described in the current issue of the journal Nature Biotechnology, can be applied to personalized cancer treatments that tailor therapy to the unique cellular makeup of each patient's tumors.
"This method promises to overcome some of the shortcomings of current TIL(Tumor infiltrating lymphocytes) based therapy, especially for patients dealing with tumors not responding to such therapies today," said Ludwig Lausanne Director George Coukos, a co-author of the study who is planning to launch a Phase I clinical trial that will test the technology in patients.

Comments

Post a Comment

Popular posts from this blog

China's First ever CRISPR Cas9 system Patent!

-
Image
Hi Folks!! Follow our blog on  Instagram China’s patent and trademark office has upheld a key patent within the portfolio of CRISPR/Cas9 intellectual property belonging to Nobel Laureate Emmanuelle Charpentier, The Regents of the University of California, and University of Vienna (known collectively as CVC), and licensed for commercial use through ERS Genomics. Dublin-based ERS Genomics said the China National Intellectual Property Administration (CNIPA) has upheld Patent No. CN201380038920.6, “Methods and Compositions for RNA-guided Target DNA Modification and for RNA-guided Transcription Regulation”. ToolGen claims that it was the  world’s first  filer of patents covering gene editing in eukaryotic cells using the CRISPR-Cas9 system. “The decision by the CNIPA fully upholding the patent further demonstrates its validity and value as part of the patent collection for use of the CRISPR/Cas9 technology,” ERS Genomics stated in announcing the Chinese decision recently. The CVC patents ha
Read more

XPOSAT - STUDY ABOUT BLACKHOLE(A GIST)

-
Image
Hi Folks!! Follow our blog on Instagram  LAB IN THE BOX XPOSAT - STUDY ABOUT BLACKHOLE (A GIST) Last year was a huge success with Chandrayaan-3. Our ISRO Scientist did a lot of unexpected acts and surprised us all. On January 1st, when this year started, India has proved to be a leading country in the world, not only on land, but also in the sky.  There are a lot of things in our universe that we don't understand. One thing that we don't understand is black holes. These black holes exist in a lot of places in space. From the fact that we are in a black hole, to the fact that all the earth and sun will disappear one day in a black hole, this is something that we don't understand. From the biggest scientist to the modern technology scientist, everyone is looking at this black hole as a mystery. To study this, India has launched a special Mission on January 1st named XPoSat( X-ray Polarimeter Satellite). On January 1st, India launched 10 different satellites throug
Read more

History of Biotechnology

-
Image
HISTORY OF BIOTECHNOLOGY: People have been harnessing biological processes to improve their quality of life for some 10,000 years, beginning with the first agricultural communities. Approximately 6,000 years ago, humans began to tap the biological processes of microorganisms in order to make bread, alcoholic beverages, and cheese and to preserve dairy products. But such processes are not what is meant today by biotechnology, a term first widely applied to the molecular and cellular technologies that began to emerge in the 1960s and ’70s. A fledgling “biotech” industry began to coalesce in the mid- to late 1970s, led by Genentech, a pharmaceutical company established in 1976 by Robert A. Swanson and Herbert W. Boyer to commercialize the recombinant DNA technology pioneered by Boyer, Paul Berg, and Stanley N. Cohen. Early companies such as Genentech, Amgen, Biogen, Cetus, and Genex began by manufacturing genetically engineered substances primarily for medical and environmental uses. For
Read more